The present invention relates to novel compounds of formula (I)

##STR00001##

to compositions comprising same, and also to the use thereof for preventing and/or cosmetically treating the signs of aging of the skin.

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-βCA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-βCA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS.

The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-βCA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-βCA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS.

The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.

The present invention relates to a computer-implemented method of determining the need of adding a mitigant to feed for inactivating viruses that might be present in said feed. The preferred mitigant is a mixture comprising benzoic acid flakes and a powder that comprises eugenol and thymol. Said mixture inactivates viruses quickly, even when added in low concentration only. This applies in particular (but not only) to porcine epidemic diarrhea vims (PEDV). The animal feed, by way of the invention, is thus rendered to be substantially free of harmful viral RNA.

The present invention relates to a computer-implemented method of determining the need of adding a mitigant to feed for inactivating viruses that might be present in said feed. The preferred mitigant is a mixture comprising benzoic acid flakes and a powder that comprises eugenol and thymol. Said mixture inactivates viruses quickly, even when added in low concentration only. This applies in particular (but not only) to porcine epidemic diarrhea vims (PEDV). The animal feed, by way of the invention, is thus rendered to be substantially free of harmful viral RNA.

The present invention relates to a computer-implemented method of determining the need of adding a mitigant to feed for inactivating viruses that might be present in said feed. The preferred mitigant is a mixture comprising benzoic acid flakes and a powder that comprises eugenol and thymol. Said mixture inactivates viruses quickly, even when added in low concentration only. This applies in particular (but not only) to porcine epidemic diarrhea vims (PEDV). The animal feed, by way of the invention, is thus rendered to be substantially free of harmful viral RNA.